Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.62 |
| ▸ | DRD2 | P14416 | 5/20 | 0.62 |
| ▸ | DRD3 | P35462 | 5/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7499884 | 0.87 | DRD4 (0.67) | DRD4DRD2DRD3 | |
| SCHEMBL6864941 | 0.82 | DRD4 (0.81) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| SCHEMBL4019882 | 0.81 | GAA (0.70) | DRD4GAAALDH1A1LMNAMAPT | |
| SCHEMBL11120307 | 0.81 | GAA (0.70) | DRD4GAAALDH1A1LMNAMAPT | |
| SCHEMBL2454168 | 0.80 | DRD4 (0.63) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6131815 | 0.79 | ALDH1A1 (0.58) | DRD4DRD2DRD3GAAALDH1A1 | |
| SCHEMBL17659005 | 0.79 | DRD4 (0.57) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| SCHEMBL8131885 | 0.79 | ATM (0.67) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| SCHEMBL13568797 | 0.79 | ALDH1A1 (0.71) | DRD4DRD2DRD3SIGMAR1GAA | |
| SCHEMBL4519472 | 0.79 | DRD4 (0.62) | DRD4DRD2DRD3SIGMAR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | TP53, MDM2, TP53BP1 | DRD4 3717/4885DRD2 3748/4885DRD3 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.